This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

BioMarin Pharmaceutical's CEO Discusses Q1 2012 Results - Earnings Call Transcript

Stocks in this article: BMRN

BioMarin Pharmaceutical (BMRN)

Q1 2012 Earnings Call

April 26, 2012 5:00 pm ET

Executives

Eugenia Shen -

Jean-Jacques Bienaimé - Chief Executive Officer and Director

Jeffrey H. Cooper - Chief Financial Officer and Senior Vice President

Henry J. Fuchs - Chief Medical Officer and Executive Vice President

Stephen Aselage - Chief Business Officer and Executive Vice President

Analysts

Bryan Huang

Cory William Kasimov - JP Morgan Chase & Co, Research Division

Navdeep Singh - Deutsche Bank AG, Research Division

Salveen J. Richter - Canaccord Genuity, Research Division

Christopher J. Raymond - Robert W. Baird & Co. Incorporated, Research Division

Joseph P. Schwartz - Leerink Swann LLC, Research Division

Tim Lugo - William Blair & Company L.L.C., Research Division

Charmaine Chan - RBC Capital Markets, LLC, Research Division

Matthew Harrison - UBS Investment Bank, Research Division

Nicholas Bishop

Liana Moussatos - Wedbush Securities Inc., Research Division

Presentation

Operator

A very good day to you, ladies and gentlemen, and welcome to your Q1 2012 BioMarin Pharmaceutical Inc. Earnings Conference Call, hosted by Eugenia Shen, Investor Relations, amongst other presenters. My name is Chris, and I'll be your conference coordinator for today. [Operator Instructions] I would just like to remind all party, this conference is being recorded for replay purposes today. Thank you. At this time, I would like to turn the call over to Eugena to start. Please go ahead.

Eugenia Shen

Thank you. On the call today is J.J. Bienaimé, BioMarin's CEO; Jeff Cooper, CFO; Hank Fuchs, Chief Medical Officer; and Steve Aselage, Chief Business Officer. This nonconfidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceuticals, including expectations regarding BioMarin's financial performance, commercial products and potential future products in different areas of therapeutic research and development. Results may differ materially depending on the progress of BioMarin's product programs, actions of regulatory authorities, availability of capital, future actions in the pharmaceutical market and developments by competitors and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, such as 10-Q, 10-K and 8-K reports.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,828.24 +0.49 0.00%
S&P 500 2,067.56 -5.27 -0.25%
NASDAQ 4,791.63 +4.3130 0.09%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs